Could a drug combo make food allergy treatment safer?
NCT ID NCT03181009
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested whether the drug omalizumab (Xolair) can make oral immunotherapy safer for people with multiple food allergies. Sixty participants aged 2 to 25 received omalizumab before gradually increasing doses of their problem foods. The goal was to see if this approach allows lower maintenance doses and reduces allergic reactions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Omalizumab (Xolair) and food flour allergens
What this could lead to
If successful, this could point toward a safer way to treat multiple food allergies at once, possibly allowing lower daily doses of allergens.
What could go wrong
This is a small, early-phase study (60 people) focused on immune markers, not long-term outcomes. Results may not apply to everyone, and allergic reactions remain a risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sean N. Parker Center for Allergy and Asthma Research at Stanford
Mountain View, California, 94040, United States
-
UCLA
Los Angeles, California, 90095, United States